PolyPid Ltd.
Controlled, extended-release, local delivery of medication at effective release rates over predetermined durations.
Israel
66 employees
Post Ipo Equity
Total: $139.80M
Biopharma, Biotechnology +2
General Information
Get notified when PolyPid Ltd. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track PolyPid Ltd.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Israel Market
Biopharma
About PolyPid Ltd.
Taxonomy: bio-pharmaceutical, surgical therapies, drug delivery, local medication, Polymer-Lipid Encapsulation matriX, surgical site infections, antibiotic resistance, clinical-stage, drug development, global healthcare, FDA-approved treatments
Funding Rounds & Investors (7)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 2 |
|
04 Jan 2024 |
| Post-IPO Debt | •••••• | 1 |
|
06 Apr 2022 |
| Series E | •••••• | 1 |
|
31 Oct 2018 |
| Series D | •••••• | 3 |
|
23 Feb 2016 |
| Series C | •••••• | 2 |
|
06 Nov 2015 |
PolyPid Ltd. Alternatives & Competitors
GIVE YOURSELF THE EDGE™
Developing best-in-class inhaled medicines for targeted treatment of life-threatening respiratory di...
Innovative Decontamination Solutions
FAQ About PolyPid Ltd.
Don't just browse. Track.
Signal Tracker monitors PolyPid Ltd. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
